Association Bone Schintigraphy with Prostate Spesific Antigen, Gleason score, and Grade group in Prostate Cancer Patient
DOI:
https://doi.org/10.29303/jku.v10i4.620Keywords:
Prostate Specific Antigen, Gleason Score group, grade group prostate cancer, bone metastasis, Tc-99m MDP bone scintigraphyAbstract
Background. Metastasis (especially in bone) in prostate cancer is often difficult to diagnose and poor prognosis. Hence, it is very important to do an early examination in detecting metastasis. Frequent bone scintigraphy indicators are prostate specific antigen (PSA) level and Gleason score (GS). This study aims to analyze how strong correlation of these factors in affecting bone metastasis in prostate cancer.
Subject and method. A retrospective cross-sectional analysis study was performed using medical records of the prostate cancer patients who underwent Tc-99m MDP bone scintigraphy at Hasan Sadikin General Hospital during January 2012 until December 2016. PSA level, GS and Gleason grade (GG) data were analyzed by bivariate and multivariate analysis.
Result. From 189 medical records, only 110 medical records were eligible to be analyzed. Bivariate analysis demonstrated statistically significant correlation for PSA level (p <0.001) and GS (p 0.05 and p 0.036) with bone metastasis in prostate cancer. Multivariate analysis showed that PSA remains the strongest factor associated with bone metastasis in prostate cancer (p 0.001).
Conclusion. From bivariate analysis, serum PSA level have statistically significant correlation with bone metastasis in newly diagnosed prostate cancer patient. In the GS dan GG classification, the higher-grade of GS or GG the higher bone metastasis in prostate cancer patient. Thus, the above results may be helpful in identifying prostate cancer patients who have a high risk for bone metastasis.
References
2. Komite Penanggulangan Kanker Nasional. Panduan penatalaksanaan Kanker Prostat. Edisi ke-1 2015; 1-23.
3. Kelompok Kerja Kanker Urologi RS. Cipto Mangunkusumo – RS Kanker Dharmais. Panduan pengelolaan kanker prostat. Interna Publishing 2009
4. Umbas R, Safriadi F. Karakteristik dan Pola penanganan kanker prostat di RS. Dr Hasan Sadikin, Bandung. Indones J Cancer.
5. R. D. Rubens and I. Fogelman (EDS.). Bone Metastases, Diagnosis and Treatment. Springer-verlag London Limited 1991.
6. McGregor B, Tulloch A, Quinlan M. The role of bone scanning in the assessment of prostatic carcinoma. Br J Urol 1978; 50: 178-181.
7. O’Donoghue E, Constable A, Sherwood T. Bone scanning an plasma phosphatase in carcinoma of the prostate. Br J Urol 1978; 50: 172-177.
8. Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology. Edisi ke-9. Canada: Elsevier Saunders; 2013.
9. Lars E, MD; Roberta M, MD, PhD; Rodolfo M, MD, FRCPath. Implication of the International Society of Urological Pathology Modified Gleason Grading System. Arch Pathol Lab Med – Vol 136, April 2012.
10. Velonas VM, Woo HH, dos Remedios CG, Assinder SJ: Current status of biomarkers for prostate cancer. Int J Mol Sci, 2013; 14: 11034–60
11. Kamaleshwaran KK, Mittal BR, Harisankar CN et al: Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy. Indian J Nucl Med, 2012; 27: 81–84
12. Altuwaijri S. Role of Prostate Specific Antigen ( PSA ) in Pathogenesis of Prostate Cancer. 2012;2012(August):331–6.
13. Mohammes A. Al-Ghazo, et al. Do all Patients with Newly Diagnosed Prostate Cancer Need Staging Radionuclide Bone scan ? A Retrospective Study. International Braz J Urol, Vol. 36 (6): 685-692, November-Desember, 2010. Doi: 10.1590/S1677-55382010000600006
14. Harnden P, Shelley MD, Coles B et al: Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol, 2007; 8: 411–19
15. Edge SB, Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 2010; 17: 1471–74
16. Yehui Chen, Yun Lin, Pin Nie, et al. Association of Prostate-Spesific Antigen, Prostate Carcinoma Tissue Gelason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Cancer. e-ISSN 1643-3750. Med Sci Monit, 2017; 23; 1768-1774. DOI: 10.12659/MSM.900977
17. Epstein JI. A new contemporary prostate cancer grading system. Pathologica. 2015;107(3–4):205–7.
18. Yasutaka Yamada, Shinichi Sakamoto, Jun Shimazaki, Masahiro Sugiura, et al. Significant prognostic difference between Grade Group 4 and 5 in the 2014 International Society of Urological Pathology Grading System for High Grade Prostate Cancer with Bone Metastasis. Asian Pasific Prostate Society. http://dx.doi.org/10.1016/j.prnil.2017.03.001.
19. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE: Predicting radionuclide bone scan findings in pa¬tients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol. 1991; 145: 313-8.